Allovir (KLRS) Competitors $2.92 -0.04 (-1.35%) As of 05/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock KLRS vs. YMAB, PROK, AVTE, CTMX, IPHA, ENGN, INBX, MNPR, CRGX, and NVCTShould you be buying Allovir stock or one of its competitors? The main competitors of Allovir include Y-mAbs Therapeutics (YMAB), ProKidney (PROK), Aerovate Therapeutics (AVTE), CytomX Therapeutics (CTMX), Innate Pharma (IPHA), enGene (ENGN), Inhibrx (INBX), Monopar Therapeutics (MNPR), CARGO Therapeutics (CRGX), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Allovir vs. Y-mAbs Therapeutics ProKidney Aerovate Therapeutics CytomX Therapeutics Innate Pharma enGene Inhibrx Monopar Therapeutics CARGO Therapeutics Nuvectis Pharma Y-mAbs Therapeutics (NASDAQ:YMAB) and Allovir (NASDAQ:KLRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation. Does the media refer more to YMAB or KLRS? In the previous week, Y-mAbs Therapeutics had 10 more articles in the media than Allovir. MarketBeat recorded 13 mentions for Y-mAbs Therapeutics and 3 mentions for Allovir. Allovir's average media sentiment score of 0.94 beat Y-mAbs Therapeutics' score of 0.33 indicating that Allovir is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Y-mAbs Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Allovir 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor YMAB or KLRS? Y-mAbs Therapeutics received 144 more outperform votes than Allovir when rated by MarketBeat users. Likewise, 64.00% of users gave Y-mAbs Therapeutics an outperform vote while only 0.00% of users gave Allovir an outperform vote. CompanyUnderperformOutperformY-mAbs TherapeuticsOutperform Votes14464.00% Underperform Votes8136.00% AllovirOutperform VotesNo VotesUnderperform Votes2100.00% Do insiders and institutionals believe in YMAB or KLRS? 70.8% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Allovir shares are owned by institutional investors. 22.5% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 32.1% of Allovir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is YMAB or KLRS more profitable? Allovir has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. Allovir's return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-28.22% -24.61% -18.49% Allovir N/A N/A N/A Do analysts rate YMAB or KLRS? Y-mAbs Therapeutics currently has a consensus price target of $15.60, suggesting a potential upside of 231.21%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Y-mAbs Therapeutics is more favorable than Allovir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.82Allovir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, YMAB or KLRS? Allovir has lower revenue, but higher earnings than Y-mAbs Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$88.66M2.41-$21.43M-$0.64-7.36AllovirN/AN/AN/AN/AN/A Which has more volatility and risk, YMAB or KLRS? Y-mAbs Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Allovir has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. SummaryY-mAbs Therapeutics beats Allovir on 9 of the 15 factors compared between the two stocks. Get Allovir News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricAllovirBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$54.61M$27.42M$2.00B$8.41BDividend YieldN/AN/A2.64%4.16%P/E RatioN/AN/A22.6719.79Price / SalesN/A26.9256.90134.05Price / CashN/AN/A51.7234.64Price / BookN/AN/A2.054.50Net IncomeN/AN/A-$330.96M$248.30M7 Day Performance4.66%8.93%1.01%0.99%1 Month PerformanceN/A-69.76%7.14%7.48%1 Year PerformanceN/A-85.19%12.46%8.72% Allovir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSAllovirN/A$2.92-1.4%N/AN/A$54.61MN/A0.00110News CoverageAnalyst UpgradeYMABY-mAbs Therapeutics3.625 of 5 stars$4.71-0.8%$15.60+231.2%-61.1%$213.29M$88.66M-8.72150News CoverageAnalyst ForecastGap DownPROKProKidney2.2589 of 5 stars$0.71-1.7%$5.00+605.8%-79.6%$211.56M$306,000.00-1.293Positive NewsAVTEAerovate Therapeutics1.7832 of 5 stars$7.25+2.3%$78.75+986.2%-98.8%$210.14MN/A-2.4220News CoveragePositive NewsGap UpHigh Trading VolumeCTMXCytomX Therapeutics4.4675 of 5 stars$2.52flat$5.33+111.6%+48.2%$203.17M$147.56M14.82170Positive NewsShort Interest ↑IPHAInnate Pharma3.2144 of 5 stars$2.16-1.8%$11.00+409.3%-21.2%$199.10M$12.62M0.00220Short Interest ↓ENGNenGene3.1628 of 5 stars$3.87-2.3%$23.29+501.7%-56.0%$197.29MN/A-6.6731News CoverageShort Interest ↓INBXInhibrx2.0907 of 5 stars$13.56-1.4%N/A-16.6%$196.30M$200,000.000.12166News CoveragePositive NewsMNPRMonopar Therapeutics2.9964 of 5 stars$32.07-1.0%$55.33+72.5%+949.6%$196.11MN/A-16.2810Positive NewsShort Interest ↓CRGXCARGO Therapeutics2.2672 of 5 stars$4.24+0.5%$15.00+253.8%-77.7%$195.97MN/A-1.00116News CoveragePositive NewsNVCTNuvectis Pharma2.8745 of 5 stars$9.17-1.9%$17.00+85.4%+35.5%$195.36MN/A-7.918Positive News Related Companies and Tools Related Companies YMAB Competitors PROK Competitors AVTE Competitors CTMX Competitors IPHA Competitors ENGN Competitors INBX Competitors MNPR Competitors CRGX Competitors NVCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepa...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresident Trump Just Warned About Economic Pain Ahead - Are You Prepared?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allovir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allovir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
